ArticleVaccines2021
Interim Estimates of COVID-19 Vaccine Effectiveness in a Mass Vaccination Setting: Data from an Italian Province.
Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 7 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Vaccine efficacy against SARS-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines: a systematic review.Frontiers in public health · 2023Pooled it
- Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis.BMC medicine · 2022Pooled it
- Pooled it
- Pooled it
- The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis.Frontiers in public health · 2022Pooled it
- Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis.Infectious diseases of poverty · 2021Pooled it
- Retrospective Cohort Analysis of Survival After SARS-CoV-2 Infection by Vaccination Status in Jamaica, April-December 2021.Vaccines · 2025Article
- Article
- Mechanistic models of humoral kinetics following COVID-19 vaccination.Journal of the Royal Society, Interface · 2025Article
- COVID-19 vaccination, all-cause mortality, and hospitalization for cancer: 30-month cohort study in an Italian province.EXCLI journal · 2025Article
- Impact of pharmaceutical and non-pharmaceutical interventions on COVID-19 in Tunisia.BMC public health · 2024Article
- COVID-19 vaccination effectiveness in the population of Friuli Venezia Giulia, North-East Italy. Control of bias associated with divergent compliance to policies in a test-negative case-control study.BMC public health · 2023Article
- Predictors of SARS-CoV-2 Infection and Severe and Lethal COVID-19 after Three Years of Follow-Up: A Population-Wide Study.Viruses · 2023Article
- COVID-19 Vaccination Effectiveness in the General Population of an Italian Province: Two Years of Follow-Up.Vaccines · 2023Article
- Development of a COVID-19 vaccine effectiveness and safety assessment system in Japan: The VENUS study.Vaccine · 2023Article
- mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic.Human vaccines & immunotherapeutics · 2022Article
- Article
- Emerging trends of research on mRNA vaccines: A co-citation analysis.Human vaccines & immunotherapeutics · 2022Article
- Despite Vaccination: A Real-Life Experience of Severe and Life-Threatening COVID-19 in Vaccinated and Unvaccinated Patients.Vaccines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This retrospective cohort study compared the rates of virologically-confirmed SARS-CoV-2 infections, symptomatic or lethal COVID-19 among the residents of the Italian province of Pescara who received one or two doses of COVID-19 vaccines, versus the unvaccinated. The official data of the National Health System were used, and a total of 69,539 vaccinated adults were compared with 175,687 unvaccinated. Among the subjects who received at least one vaccine dose, 85 infections (0.12%), 18 severe and 3 lethal COVID-19 cases were recorded after an average follow-up of 38 days. Among the unvaccinated, the numbers were 6948 (4.00%), 933 (0.53%) and 241 (0.14%), respectively. The serious adverse event reports-yet unconfirmed-were 24 out of 102,394 administered doses. In a Cox model, adjusting for age, gender, and selected comorbidities, the effectiveness of either BNT162b2, ChAdOx1 nCoV-19 or mRNA-1273 vaccines was higher than 95% in preventing infections (mostly due to B.1.1.7 variant), symptomatic or lethal COVID-19. No differences were observed across genders, and among the 691 subjects who received the second dose of vaccine later than the recommended date. Although preliminary, these findings support current immunization policies and may help reducing vaccine hesitancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.